VivoSeq
Cardiovascular

Peripheral Arterial Disease

88

Pipeline Programs↗

18

Active Trials↗

51

Companies Involved↗

Peripheral Arterial Disease is a moderately active landscape with 88 programs across 51 companies. The most active players are Eastern Cooperative Oncology Group, Takeda, Daiichi Sankyo. 25 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

27/100

Mech. Concentration

8/100

Completion Rate

76/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2C

CardioVascular BioTherapeutics, Inc.

1 program

Phase 2BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

1 program

Phase 2P

POLYSAN Scientific & Technological Pharmaceutical Company

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical18

Ranolazine

Menarini International Operations Luxembourg SA

Telmisartan

Boehringer Ingelheim

Iloprost

BTG International Inc.

Paclitaxel

Teva

Evolocumab

Amgen

Phase 17

Rivaroxaban

Wim Janssens

Simvastatin

Organon and Co

Filgrastim

Eastern Cooperative Oncology Group

Angiotensin-(1-7)

University of Arizona

Pioglitazone

Takeda

Phase 222

Canakinumab

Novartis

Sodium Nitrite

Hope Pharmaceuticals

L-Citrulline

Asklepion Pharmaceuticals, LLC

Ghrelin

University of Aarhus

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Phase 316

Semaglutide

Novo Nordisk

Orforglipron

Eli Lilly

Sildenafil

Viatris Specialty LLC

Resveratrol

National Cancer Institute (NCI)

Metoprolol Succinate

AstraZeneca

Approved25

Clopidogrel

Sanofi

Cilostazol

Otsuka

Ticagrelor

AstraZeneca

Ezetimibe

Organon and Co

Allopurinol

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

92%

Small molecule

88 of 96 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody33%Cell therapy33%Protein / enzyme11%Peptide11%

Small molecule leads; the ring shows all 96 classified programs, each share of the total. Modality classified for 98% of 102 pipeline programs.

Analysis

Trial Status

86

clinical trials

Completed41 · 48%
Unknown status14 · 16%
Recruiting11 · 13%
Terminated9 · 10%
Withdrawn4 · 5%
Active, not recruiting4 · 5%
Other3 · 3%

Clinical Trials

Trial Activity

86 trials

Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
Recruiting·BBiotechnology Institute IMASD·Phase 4·NCT06952998·38 enrolled
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease
Recruiting·CCell Biopeutics Resources Sdn Bhd·Phase 4·NCT05854641·10 enrolled
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
Recruiting·EEmory University·Phase 2·NCT03304821·176 enrolled
Carnosine for Peripheral Arterial Disease Patients
Recruiting·—·Phase 1/2·NCT05371145·20 enrolled
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
Recruiting·—·Phase 1/2·NCT06480760·144 enrolled
Intravascular Ultrasound Imaging Guidance for Optimal Revascularization of Limb Arteries
Recruiting·BBaylor Research Institute·Preclinical·NCT07353905·350 enrolled
A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07223593·1,205 enrolled
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy
Recruiting·—·Preclinical·NCT06321575·159 enrolled
Use of Thermal Imaging Camera to Assess Perfusion Before and After Vascular Intervention
Recruiting·UUniversity Hospitals Cleveland Medical Center·N/A·NCT06544135·25 enrolled
Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)
Recruiting·CCentre Hospitalier le Mans·Preclinical·NCT04800276·70 enrolled
Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study (PREMISE-ILIAC Study)
Recruiting·—·N/A·NCT07672249·98 enrolled
REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD
Active, not recruiting·National Heart Centre Singapore·Phase 2·NCT05912218·70 enrolled
VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.
Active, not recruiting·RRennes University Hospital·Phase 3·NCT03686306·106 enrolled
An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Active, not recruiting·MMicro Medical Solution, Inc.·N/A·NCT04110327·300 enrolled
A Prospective PMCF Study of Paclitaxel Drug-coated Balloon Angioplasty for the Treatment of Symptomatic Peripheral Arterial Disease
Active, not recruiting·OOrbusNeich·N/A·NCT06832631·284 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)